Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Leveraged buyout transaction
Probably, Dr. Chain and the board, already at Feb. 13, 2013 in their business plan (see letter to shareholder) had planned the creation of a New Company (Chain Pharmaceuticals).
New Company to make a leveraged buyout transaction to acquire all the ILNS shares, held mostly by big basher and restore oxygen to Intellect.
Therefore, I believe a possible buyot by Dr. Chain with financing from banks, funds or other ...
Shareholders do not worry if the project goes in port, Chain Pharmaceuticals and Intellect will be a single company. In addition, the letter of intent signed by Dr. Chain with Chiesi Pharma, will lead to the final signature with Intellect to acquire the rights of CHF5074. Of course, will also be possible partnerships with big Pharma at the same time.
The leveraged buyout usually involves the creation of a special purpose vehicle set up ad hoc and called NewCo ( Chain Pharmaceuticals ), in which the sponsors of the operation and the various lenders entering the venture capital and debt capital necessary for the acquisition.
.
What do you think about?
By carefully reading the letter dated June 20, we can exclude an imminent sale of Intellect.
Therefore, in the previous letter, dated June 18, remain only words "related transaction". (See meaning to bottom page)
If since June 20, there have been no new developments with other Big Pharma, we can believe that there will be a partnership with ViroPharma to CONJUMAB-A candidate for Age Related Macular Degeneration (AMD).
Or, Pfizer could buy the patent ponezumab, together annulment of the lawsuit.
-------------------------------------------------
Letter to shareholder dated June 20, 2013 :
Conclusion
Intellect has a bright future ahead. We are confident in our ability to attract new leadership who will lead the company to success.
http://ir.stockpr.com/intellectns/press-releases/detail/924/intellect-neurosciences-inc-issues-letter-to-shareholders
Letter to shareholder dated June 18, 2013 :
... In making this announcement, Intellect offers no assurance that the review of possible alternatives will result in a sale or related transaction and the company does not intend to disclose developments until such time as the Board of Directors approves or has a transaction(s) to recommend to stockholders, or otherwise deems further disclosure appropriate.
http://ir.stockpr.com/intellectns/press-releases/detail/914/intellect-neurosciences-engages-evli-corporate-finance-to-explore-strategic-alternatives-to-maximize-shareholder-value
Definition of: Related Transaction
A business deal or arrangement between two parties who are joined by a special relationship prior to the deal. For example, a business transaction between a major shareholder and the corporation, such as a contract for the shareholder's company to perform renovations to the corporation's offices, would be deemed a related-party transaction.
.
I believe that Dr. Chain and the board are following step by step the plan as it appears on letter to shareholders of the Feb. 13, 2013 :
... In 2013 we plan to move forward aggressively with our CONJUMAB and tau immunotherapy programs. These activities are expected to generate data that will increase the enterprise value of each program and attract new partnership opportunities that could result in substantial license revenues. ...
http://ir.stockpr.com/intellectns/press-releases/detail/893/intellect-neurosciences-issues-letter-to-shareholders
.
http://www.cerespir.com/
Domain Name: CERESPIR.COM
Registrar: GODADDY.COM, LLC
Whois Server: whois.godaddy.com
Referral URL: http://registrar.godaddy.com
Name Server: NS31.DOMAINCONTROL.COM
Name Server: NS32.DOMAINCONTROL.COM
Status: clientDeleteProhibited
Status: clientRenewProhibited
Status: clientTransferProhibited
Status: clientUpdateProhibited
Updated Date: 01-may-2013
Creation Date: 01-may-2013
Expiration Date: 01-may-2015
-------------------------------------------------------
Two days after, Dr. Chain’s resignation letter dated May 3, 2013
http://ih.advfn.com/p.php?pid=nmona&article=57512015
I think CERESPIR is only a empty box to park temporarily CHF 5074.
.
NOTE:
Intellect has been mentioned twice in steps 2 and 5.
Dr. Chain seems genuinely interested to future of Intellect and not interested in his personal gain.
Contrary to Report Filing (8-K) dated May 10, 2013 ...
What do you think about?
http://ih.advfn.com/p.php?pid=nmona&article=57512015
.................................................................................
I believe that future of Intellect is already written!
Letter to shareholders - March 29, 2013:
... trip to Europe, which included 27 meetings in 10 days!
1) ... The vast majority of these meetings had to do with the strategic plan I outlined in my letter to you of February 13, 2013: namely, to move forward aggressively with our CONJUMAB-A and tau immunotherapy programs, which have attracted interest from the pharmaceutical industry and institutional investors, especially in Europe. ...
2) ... I was encouraged by several examples of assays being developed to evaluate drug compounds targeting tau that could be helpful to Intellect. ... ( maybe CHF 5074 ? )
3) ... Some of these meetings were with large pharmaceutical companies to discuss potential partnering relationships. ...
4) ... Other pre-arranged meetings were with specialist contract research organizations and regulatory specialists that can help enormously with creating a high-value drug compound dossier to facilitate partnering activities in the future. ... ( maybe Evli ? )
5) ... I was pleased to discover a number of newly developed sophisticated tools that could be applied to test and optimize Intellect's drug candidates. ...
6) ... Back in New York, we have been exceedingly busy following up on ongoing licensing conversations and adding further detail to the development programs so that we are in position to proceed aggressively pending securing adequate financial resources. ...
.
I believe the future of Intellect is already written!
I have selected the phrases of Dr. Chain in a letter to shareholders:
March 29, 2013
... trip to Europe, which included 27 meetings in 10 days!
1) ... The vast majority of these meetings had to do with the strategic plan I outlined in my letter to you of February 13, 2013: namely, to move forward aggressively with our CONJUMAB-A and tau immunotherapy programs, which have attracted interest from the pharmaceutical industry and institutional investors, especially in Europe. ...
2) ... I was encouraged by several examples of assays being developed to evaluate drug compounds targeting tau that could be helpful to Intellect. ( CHF 5074 ? ) ...
3) ... Some of these meetings were with large pharmaceutical companies to discuss potential partnering relationships. ...
4) ... Other pre-arranged meetings were with specialist contract research organizations and regulatory specialists that can help enormously with creating a high-value drug compound dossier to facilitate partnering activities in the future. ( Evli ? ) ...
5) ... I was pleased to discover a number of newly developed sophisticated tools that could be applied to test and optimize Intellect's drug candidates. ...
6) ... Back in New York, we have been exceedingly busy following up on ongoing licensing conversations and adding further detail to the development programs so that we are in position to proceed aggressively pending securing adequate financial resources. ...
-------------------------------------------------------------------------
Note:
Intellect has been mentioned twice in steps 2 and 4.
He seems genuinely interested in the future of the intellect and not interested in his personal gain.
-
Do not worry, we'll see Bid / Ask to a minimum of $ 1000 for each exchange ...
It will never be as now of $ 50 for each exchange ...
I believe that the weekly allowance of a teenager is superior to exchanges of some traders!
-
Unfortunately, there is another theory
Hanlon's Razor:
Never attribute to malice that which can be adequately explained by stupidity.
-
Strategic Partnerships and Dr. Chain's short-strange story:
Strategic Partnerships
http://www.intellectns.com/company-info/strategic-partnerships
------------------------------------------------------------------------------------------
and Dr. Chain's short-strange story:
March 29, 2013
... Back in New York, we have been exceedingly busy following up on ongoing licensing conversations and adding further detail to the development programs so that we are in position to proceed aggressively pending securing adequate financial resources. ...
http://ir.stockpr.com/intellectns/press-releases/detail/904/intellect-neurosciences-issues-letter-to-shareholders
the month later ( 35 days ):
Dr. Chain’s resignation letter dated May 3, 2013
http://ih.advfn.com/p.php?pid=nmona&article=57512015
3 days later:
Chain Pharmaceuticals LLC - filing date May, 6:
http://www.bizapedia.com/de/CHAIN-PHARMACEUTICALS-LLC.html
3 months later:
July 30, 2013
Intellect Neurosciences, Inc. announced today it has retained Chain Pharmaceuticals LLC as a consultant to assist the company ...
http://ir.stockpr.com/intellectns/press-releases/detail/934/intellect-neurosciences-retains-chain-pharmaceuticals-llc
---------------------------------------------------------------------------------------------
I can't believe it is ridiculous comic comedy ...
I prefer to believe that it was all planned ahead in March ...
-
Website update Intellect - missing the photo of Dr. Chain, Blog, ...
Probably the update was not yet completed ...
http://www.intellectns.com/
.
Be greedy when others are fearful. Be fearful when others are greedy.
Warren Buffett
The time is running out, now is best time to buy at bottom price.
Then, it will be like chasing a train just left the station ...
Tencoin
.
ILNS value ... Who wants to make serious analysis?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90631938
-
ILNS value, in comparison to DuoCort Pharma = ?
----------------------------------------------------------------------------
Intellect Neurosciences Engages Evli Corporate Finance to Explore Strategic Alternatives to Maximize Shareholder Value. ...
... Evli Corporate Finance acted as Advisor to Duocort Pharma upon the sale of the company to ViroPharma. ...
http://ir.stockpr.com/intellectns/press-releases/detail/924/intellect-neurosciences-inc-issues-letter-to-shareholders
----------------------------------------------------------
October 27, 2011
ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
Transaction Terms
On approval of Plenadren, ViroPharma will acquire DuoCort Pharma AB for an upfront closing cost of 220 million SEK, or $33.6 million USD, and potential additional aggregate consideration of 860 million SEK or approximately $131 million USD. Of that, 160 million SEK (approximately $25 million USD) relate to specific regulatory milestones; and 0 to 700 million SEK ($0 to approximately $107 million USD) are commercial milestones based on the success of the product.
About DuoCort Pharma
DuoCort Pharma is a drug development company focused on improving glucocorticoid therapy. The company has its origins among researchers at the Sahlgrenska University Hospital in Gothenburg and at Uppsala University in Sweden. DuoCort Pharma has developed Plenadren®, an improved glucocorticoid replacement therapy for patients with adrenal insufficiency, which is a rare disease. DuoCort Pharma has orphan drug designations in Europe and the USA for Plenadren. Plenadren is a once daily, dual-release hydrocortisone oral tablet. It has an outer layer that releases the drug immediately and an inner core that releases the drug over the day. The tablets come in both 5 mg and 20 mg strengths.
http://ir.viropharma.com/releasedetail.cfm?ReleaseID=618458
-------------------------------------------------------------------------
November 15, 2011
ViroPharma Completes Acquisition of DuoCort Pharma AB
http://ir.viropharma.com/releasedetail.cfm?ReleaseID=623909
-
If your feeling is correct, it means that they are waiting for the conclusion of the agreement with ILNS.
Soon the great news for Phase 2 and for acquisition of ILNS with all patents.
Then the proposal to shareholders ILNS: 1 share ViroPharma in exchange for 20 shares ILNS!
In the future, the legal battle with Pfizer will be with ViroPharma ...
Good luck to all investors ...
The word Phase 2, misleads the investors - probably, we must to understood as follows:
Status ViroPharma is conducting 2nd Study of Phase 1 - enabling toxicology studies with VP 20629; the company expects to initiate 2nd Study ( new one ) of Phase 1 - clinical testing in late 2012/early 2013.
---------------------------------------------------------------------------
VIROPHARMA Reply to my question - May 2013:
Thanks for your email. We have not exactly classified the studies we are about to initiate as either a phase 1 or 2 type study. I do understand though that our verbal communications around the program perhaps have been a little confusing.
All I can say is that we are planning to initiate human clinical testing with this compound in the second half of this year.
See my post to May 12, 2013:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87828371
.
Ponezumab - Phase 2 , not Phase 1
Official Title: A Phase 2, Randomized, Double Blind Placebo Controlled Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of PF-04360365 (Ponezumab) in Adult Subjects With Probable Cerebral Amyloid Angiopathy
http://www.clinicaltrials.gov/ct2/show/NCT01821118?term=ponezumab+%28PF-04360365%29&rank=5
-
ViroPharma Announces Second Quarter 2013 Financial Results ...
... VP-20629 for Friedreich's Ataxia (FA) – We initiated a single and multiple oral dose safety and tolerability study in patients in 2013. The company anticipates completion of enrollment in the first half of 2014. ...
http://finance.yahoo.com/news/viropharma-announces-second-quarter-2013-113000352.html
-
I believe/feel that Viropharma notify of great news about VP 20629 - Friedreich’s Ataxia, when they will finish to making the buyout.
They are doing a slow buyout to avoid a sudden rise in the price of the shares.
They want to buy low price ...
Is it possible "VP 20629 fast track" as news?
--------------------------------------------------------------------
ViroPharma - Strong Buyback Activity.
See How ViroPharma Ranks Among Analysts' Top Picks With Strong Buyback Activity:
http://www.forbes.com/sites/dividendchannel/2013/07/24/see-how-viropharma-ranks-among-analysts-top-picks-with-strong-buyback-activity/?partner=yahootix
-
I mailed to Maza about "Bapineuzumab" 20 days ago, because he didn't write no word in the last letter to shareholders.
My question to Maza:
Has been abandoned forever Bapineuzumab, or are continuing experiments/studies other BioPharma?
I received reply By Maza 3 hours later my email:
Dr. Chain has always occupied with Bapineuzumab and now I have not had time to study the situation. For this reason I chose not to write anything on last letter to shareholders.
..........................................................
We can think optimistically about the words that Maza has not been able or willing to say ...
-
Only small molecule for Friedreich's Ataxia VP 20629 can bring cash immediately.
Status:
... the company expects to initiate Phase 2 clinical testing in late 2012/early 2013.
Question 1:
It is coming late 2013 ... What are they waiting for?
Question 2:
No word about Friedreich’s Ataxia VP 20629 ... WHY ?
Maybe something is cooking in the pot!
ViroPharma - JMP Securities 2013 Healthcare Conference
Page 1:
...... We also have a couple of investigator-initiated studies ongoing one in a condition called Neuromyelitis Optica, NMO and other in Autoimmune Hemolytic Anemia and the third which is more of a preclinical investigator-initiated study in Refractory PNH. All three of these investigator-initiated studies are ongoing and we may see data. As you probably know, we work at the back-end of our investigators in terms of timeframes for the data. ..........
Page 2:
........... if you are an investor who love his dreams, we have some wonderful dreams that we're working on at ViroPharma, we're very excited about those. And we look forward to sharing more data with you in the months ahead. ........
http://www.earningsimpact.com/Transcript/82016/VPHM/ViroPharma-Incorporated---JMP-Securities-2013-Healthcare-Conference
-
Same question ... many replies ...
Currently or previously wording is common in legal language when it comes to ownership, Lawyers use that language to stay in the middle of an ownership claim because an iten can be sold after you submitt your claim or it can be sold as you are speaking, henceforth the phrase currently or previously owned.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87821965
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87836578
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87828123
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87833362
-
ViroPharma - JMP Securities 2013 Healthcare Conference
No word about Friedreich’s Ataxia VP 20629 ... WHY ?
Maybe something is cooking in the pot!
Page 1:
...... We also have a couple of investigator-initiated studies ongoing one in a condition called Neuromyelitis Optica, NMO and other in Autoimmune Hemolytic Anemia and the third which is more of a preclinical investigator-initiated study in Refractory PNH. All three of these investigator-initiated studies are ongoing and we may see data. As you probably know, we work at the back-end of our investigators in terms of timeframes for the data. ..........
Page 2:
........... if you are an investor who love his dreams, we have some wonderful dreams that we're working on at ViroPharma, we're very excited about those. And we look forward to sharing more data with you in the months ahead. ........
http://www.earningsimpact.com/Transcript/82016/VPHM/ViroPharma-Incorporated---JMP-Securities-2013-Healthcare-Conference
.
... Global market for Huntington’s Disease Therapeutics is projected to exceed US$870 million by 2018, ...
... Major players in the marketplace include Alnylam Pharmaceuticals Inc., AmpliPhi Biosciences Corp, Ceregene Inc., Cortex Pharmaceuticals Inc., Intellect Neurosciences Incorporation, Prana Biotechnology Limited, Raptor Pharmaceuticals Corp, Teva Pharmaceutical Industries Ltd., Trophos S.A., Valeant Pharmaceuticals International Inc., and Vertex Pharmaceuticals Incorporated. ...
http://www.watchlistnews.com/2013/07/01/unmet-medical-needs-drive-the-global-huntingtons-disease-therapeutics-market-according-to-new-report-by-global-industry-analysts-inc/
-
-
-
-
-
At the end of the agreements, probably ViroPharma will offer $ 0.28 per share to ILNS shareholders or 1 share VPHM per 100 shares ILNS.
What will be better accept?
-
-
-
-
-
MAZA WHY SHOULD SELL NOW ?
1) We have a good chance of receiving the first royalty by Viropharma.
2) Pay the traitor Dr. Chain.
3) Purchase by Chiesi Pharma rights the novel anti-Alzheimer's compound CHF5074.
4) Become a small BioPharma listed on Nasdaq.
5) Put in the first place the interests of shareholders and the Company ILNS.
It 's impossible?
-
-
-
-
-
The 2013 scenario of ILNS is more complicated than a thriller ...
No longer able to follow a logical thread ...
It seems correct everything and the opposite of everything ...
-
-
-
-
-
It is probably you did not read the news of Viropharma ...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87828371
-
-
-
-
-
Thanks for looking on the owner of the patents.
I sought the owner of the patent on the drug CHF5074 of Chiesi Pharmaceuticals Inc.
Unfortunately I did not find the owner of the patent on your link ...
I think it's important to understand whether the patent belong to CHIESI Pharma or if it has been sold to ILNS or other Biopharma.
However, CHIESI Pharma since 2008 began offering to license the patent on the drug-CHF5074.
Perhaps the license is too expensive or the drug is not interesting.
It is strange that after 5 years, no Big Pharma has bought the license or patent.
-
-
-
-
-
Reply email from Viropharma:
-----------------------------------------------------
My question to VIROPHARMA:
Please, I would like know the exact phase/study of VP 20629 ( Phase 2 or Phase 1 ??? )
Link 1 http://www.viropharma.com/pipeline/vp20629.aspx
Status ViroPharma is conducting Phase 2-enabling toxicology studies with VP 20629; the company expects to initiate Phase 2 clinical testing in late 2012/early 2013.
Or, Link 2 ( May 1, 2013 ) http://ir.viropharma.com/releasedetail.cfm?ReleaseID=760844
VP-20629 for Friedreich's Ataxia (FA) — We expect to initiate a single and repeat dose phase 1 study in patients in 2013.
---------------------------------------------------------------------
VIROPHARMA Reply:
Thanks for your email. We have not exactly classified the studies we are about to initiate as either a phase 1 or 2 type study. I do understand though that our verbal communications around the program perhaps have been a little confusing.
All I can say is that we are planning to initiate human clinical testing with this compound in the second half of this year.
-
-
-
-
-
CHF5074 is currently or previously owned by Chiesi Farmaceutici S.p.A
It could be a typo (or / and) - maybe there are secret negotiations underway for the sale of the patent ...
I found the website (Italian / English top right) and I realized that ILNS is a gnat in front of CHIESI.
Therefore, Dr. Chain could acquire only the patent CHF5074 and never buy Chiesi Pharmaceutical.
--------------------------------------------
Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 25 direct branches, 3 manufacturing plants and 4 research centres situated in Parma (Italy), Paris, Rockville (Maryland - USA) and Chippenham (UK). ............
http://www.chiesigroup.com/web/guest/il-gruppo-chiesi?idt=194288
--------------------------------------------
...... It is also responsible for planning and conducting the Phase 1 and Phase 2 clinical studies for Chf 5074, a potential new drug in the treatment of Alzheimer’s disease.
http://www.chiesigroup.com/web/guest/chi-siamo/il-gruppo-chiesi/chiesi-nel-mondo/usa
http://clinicaltrials.gov/archive/NCT01303744
-
-
-
-
-
I think that Dr. Chain is a refined mind.
He as well as being a scientist is also an astute businessman.
Dr. Chain, after the resignation, probably will buy ILNS in cash.
Only he has all the options and the ability to purchase ILNS for less than a million dollars.
Soon after, Dr. Chain will purchase Chiesi Farmaceutici SpA, a pharmaceutical company based in Parma, Italy.
Dr. Chain would not abandon his son ILNS only for money ...
I bet you will ILNS to $ 1 or more, by the end of 2013 !
-
-
-
-
-
Why David Blech gets four years and manipulators of today on ILNS don't go to jail?
Who are driving down ILNS share prices?
All shareholders would like understand ...
-
-
-
-
-
I sent an email to Viropharma and I asked for clarification on the news today, in reference to VP-20629
If I receive a reply, I will post it on this forum.
I posted on Saturday, February 23, 2013 the following status ( it is old ):
Status
ViroPharma is conducting Phase 2-enabling toxicology studies with VP 20629; the company expects to initiate Phase 2 clinical testing in late 2012/early 2013.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84928748
We expect to initiate a single and repeat dose phase 1 study in patients in 2013.
VP-20629 for Friedreich's Ataxia (FA)
What does this mean ?
http://ir.viropharma.com/releasedetail.cfm?ReleaseID=760844
-
-
-
-
-
Please, can you post the LINK ... ?
Lonza Business Performance on Track - April 25
... Pharma&Biotech Market Segment
The Pharma&Biotech market segment saw a good pipeline development across all technologies. As expected the segment had a lower capacity utilization in the first quarter of the year due to higher product changeover because of new project introductions as well as project delays at customers. Based on contracts and negotiations there will be a continuous ramping-up of the entire network in the quarters ahead. Various long-term supply agreements for small molecule products were signed during the first quarter 2013 and the expansion of antibody drug conjugate plant in Visp is on track. Biological Manufacturing saw good pipeline development. The resolving of the Hopkinton, MA (USA) manufacturing issues remains a key priority and we are working diligently to address the manufacturing and process issues. The pipeline for cell and viral was strong with high number of new product candidates and for new clients. Lonza‘s Singapore cell therapy facility is on-line and the first GMP lots of cell therapy products were produced. ...
http://www.lonza.com/about-lonza/media-center/news/2013/130425-q1-business-update-e.aspx
----------------------------------------------------------------------------
http://www.intellectns.com/internal-pipeline
Internal Pipeline
... Additionally, CONJUMAB-A is Intellect's newly introduced platform technology for a novel class of therapeutics for treatment of Alzheimer’s disease and other proteinopathies based on antibody-drug conjugates (ADCs). The new ADC- based technology has the potential to improve on current methods of passive immunotherapy by increasing clearance of amyloid proteins while delivering potent cytoprotective molecules to sites of damage in the brain and other organs. CONJUMAB-A is designed to reduce inflammation caused by amyloidosis while avoiding vasogenic edema, a side effect of plaque dissolution that occurs in some patients. The company’s lead CONJUMAB-A candidate is IN-N01-OX2, a non-activating, stabilized IgG4 humanized antibody specific for beta amyloid protein conjugated to melatonin, which is a naturally occurring molecule with potent anti-oxidant and anti-fibrillogenic properties. ...
-
-
-
-
-
Can you understand the source of repetitive false orders?
All shareholders would like understand who are the conspirators ...
-
-
-
-
-
Does somebody want new Reverse Split ?
I can't understand the sale to $ 0.009 ( everyday ) ...
Who are they ?
-
-
-
-
-